The Significance of Imunohematology Research in Relation to Menagement of Hemolitical Diseases of the Newborn in Republic of Macedonia


  • Emilija Velkova Institute of Transfusion Medicine in Republic of Macedonia, Vodnjanska 17, 1109 Skopje



аllosensibilisation, alloantibody, Haemolitic Desease of the Foetus and Newborn, immunization, Red Blood Cells, antenatal – postnatal, profilaxis, IgIG (hyperimun gamaglobulin)


AIM: Prompt discovery of allosensibilisation to RBC’s antigens during pregnancy and successful management of HDFN in Republic of Macedonia, in order to decrease morbidity and mortality of the fetus and the newborn.

MATERIALS AND METHODS: The study comprises in total 23,800 patients, 14,858 pregnant women and 8,842 newborn babies.

RESULTS: The screening and identification of anti RBC’s antibodies detected in total 216 alloantibodies, out of which 81% (175) had a clinical significance. Out of the above mentioned 164 alloantibodies (65.9%) belong to the Rh system. The most often reason for a severe hemolytic disease is the anti-D antibody. The HDFN symptoms of mild and moderate degree demonstrated 32.5%, and 18.9% had symptoms of severe fetal suffering, and almost half of them (48%) were with or with mild HDFN and had no need of therapy. In 15% it was about alloantibodies of other Rg antigens: anti-C, anti-E and anti-c, at which in most cases there were no signs of HDFN, or it showed weak symptoms (89%), just one case of anti-c ended with intrauterine death.

CONCLUSIONS: Anti D antibody represents the most often reason for severe HDFN and displays a need of intrauterine transfusion and exsangvino transfusion. Anti-c is the only antibody that demonstrated the same potential for severe HBN as the anti-D. The most often reason for alloimmunisation of the mother is the lack of RhIG prophylaxis (97.8): postnatal, antenatal and in case of possible sensible conditions during pregnancy. Thus, there is a need and an outmost importance of elaboration and adoption of the National programe for RhIG prophylaxis in Republic of Macedonia.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Voughan J I, Warwick R, Letsky E, Nicolini U, Rodeck C H, Fisk N, Erythropoetic suppression in fetal anaemia beacouse of KELL alloimmunisation. American Journal of Obstetrics and Gyneacology. 1994; 171 (1): 247-251.

Kennedy MS, Wilson S and Kelton JG. eds. Perinatal Transfusion Medicine, ArlingtonVA: American Assosiation of Blood Banks, 1990.

Issit PD, FIMLS, Biol FI, Path MRC. Applied Blood Group Serology. Mondgomery scientific publication Miamy: Florida, USA, 1991.

Szymanski IO, Odgren PR, Fortier NL, Snyder L. Red blood cell associated IgG in normal and pathologic states. Blood. 1980; 55(1):48-54.

Contreras M. Cellular antigens as immunogens in blood transfusion and pregnancy, in: Immunogenetic aspects of blood transfusion and bone marrowtransplantation Proceedings of the European School of Transfusion Medicine. 1998: 10-5.

Greer JP, Foester J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE. Alloimmnune hemilitic disease of the fetus and newborn, Wintrobe’s Clinical Hematology, 11th ed., Philadelphia, PA: Lippincot, Williams & Wilkins, 2004.

Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolitic disease of the newborn in the United States. J Am Med Assoc.1991; 265(24):3270-4.

Bowman JM. Treatment options for the fetus with alloimmune hemolytic disease. Transf Med Rev. 1990;4:191-207.

Van der Schoot CE, Tax GH, Rijnders RH, de Hass M, Cristiansen GC. Prenatal typing of Rh and Kell blood group system antigens: the edge of watershed. Transtos Med Rev. 2003;17:31-44.

College of American Pathologist. CAP survey final critique J-B, 2005.

Overbeeke MAM. Haemolytic disease of the newborn:clinical aspects, in: Red cell immunohaematology 1998, Proceedings of the European School of Transfusion Medicine. 1998; 73-8

Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Reviews. 2000; 14: 44-61.

Joy SD, Rossi KQ,Krugh D, O’Shaugnessy RW. Managament of pregnancies complicated by anty-E alloimunisation. Obstet Gynecol. 2005;105(1):24-28.

Hackney DN, Knudson EJ, Rossi KQ, Krough D, O’Shaugnessy RW. Managament of pregnancies complicated by anty-c alloimunisation. Obstet Gynecol. 2004;103(1):24-30.

Moise KJ. Fetal anemia due to non-Rhesus-D-red-cell alloimunisation. Semin Fetal Neonatal Med. 2008;13(4):207-214.

Proeg CPB, Anthony S, Rijpsta A, Verkerk PH. Process Monitoring Pre- and Postnatal Screening 2003. Leiden. TNO Quolity of Life, 2006.

MacCenzie IZ, Findlay J, Thompson K, Roseman F. Compliance with routine antenatal rhesus D profilaxis and the impact of sensitisations: observation over 14 years. BJOG. 2006;113(7):839-843.

Hadley A, Soothill P. Ed: Alloimmune Disorders of Prenancy. Cambrige University Press, 2002.




How to Cite

Velkova E. The Significance of Imunohematology Research in Relation to Menagement of Hemolitical Diseases of the Newborn in Republic of Macedonia. Open Access Maced J Med Sci [Internet]. 2014 Sep. 15 [cited 2021 Oct. 24];2(3):456-560. Available from:



B - Clinical Sciences